Recent Updates — CMND

Clearmind Medicine Inc. announced a reverse stock split of its common shares at a ratio of 1-for-8, consolidating eight pre-split shares into one post-split share. The transaction will reduce the number of issued and outstanding ordinary shares from 4,059,227 to approximately 507,404, with no fractional shares issued; any fractions are rounded up to the nearest whole share. Proportionate adjustments apply to the exercise prices and share counts of all outstanding options and warrants. The new CUSIP number is 185053709, and trading on the Nasdaq Capital Market under the split terms begins on October 5, 2026. Clearmind Medicine Inc. operates in the biotechnology industry, focusing on the development of psychedelic-based therapeutics for mental health disorders.

Clearmind Medicine Inc. announced the enrollment of its first patients with Alcohol Use Disorder (AUD) in the ongoing clinical trial evaluating CMND-100, a proprietary psychedelic-based treatment candidate. The initial two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first administration of CMND-100 to AUD subjects. This milestone follows previous evaluations of CMND-100 at multiple doses in healthy participants and represents significant progress toward key clinical milestones for safety, tolerability, pharmacokinetics, and preliminary efficacy. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics for neuropsychiatric, metabolic, and addiction disorders.

Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements for the three and nine months ended July 31, 2026. The company reported a net loss of $907,291 for the quarter and $6,809,527 for the nine-month period, with cash and cash equivalents increasing to $12,035,210 from $3,923,058 at the prior year-end. The filing details significant capital raising activities, including the conversion of $8,899,559 in convertible promissory notes into 1,778,626 common shares and proceeds of $7,245,761 from equity issuances. Additionally, the company recorded a gain on the revaluation of derivative warrant liabilities of $496,061 for the nine months ended July 31, 2026. Clearmind Medicine Inc. operates in the biopharmaceutical industry and is engaged in clinical-stage development of psychedelic-derived neuroplastogens for neuropsychiatric disorders.

Clearmind Medicine Inc. announced that Yale University’s Institutional Review Board has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100, following positive safety results from Part A. The approval enables the company to accelerate enrollment at Yale School of Medicine’s Department of Psychiatry, joining other active sites including Johns Hopkins University and Israeli medical centers. Part A involved 24 participants across four ascending-dose cohorts who successfully completed treatment with no serious adverse events observed, reinforcing the compound's safety profile for treating Alcohol Use Disorder. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric and addiction disorders.